Importantly, given the crucial roles of PAF-R in modulating the efficacy of therapeutic agents, these studies provide the rationale of evaluating chemotherapeutic MVP-based approaches to combat pancreatic cancer. The gene discussed is PTAFR; the disease is pancreatic neoplasm.